SHIRE PLC
|
||||
By:
|
/s/ T May
|
|||
Name: |
Tatjana May
|
|||
Title: |
General Counsel
|
EXHIBIT INDEX
|
|
Number
|
Description
|
99.01
|
Press release dated January 10, 2014
|
Press Release
|
|
www.shire.com
|
Investor Relations
|
||
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
Media
|
||
Jessica Mann
|
jmann@shire.com
|
+44 1256 894 280
|
Gwen Fisher
|
gfisher@shire.com
|
+1 484 595 9836
|
|
·
|
Shire's proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement;
|
|
·
|
a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
|
|
·
|
ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma's business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; and
|
|
·
|
difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all;
|